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Cystine-knot peptideCyclotides belong to the family of cyclic cystine-knot peptides and have shown promise as scaffolds
for protein engineering and pharmacological modulation of cellular protein activity. Cyclotides are
characterized by a cystine-knotted topology and a head-to-tail cyclic polypeptide backbone. While
they are primarily produced in plants, cyclotides have also been obtained by chemical synthesis.
However, there is still a need for methods to generate cyclotides in high yields to near homogeneity.
Here, we report a biomimetic approach which utilizes an engineered version of the enzyme Sortase
A to catalyze amide backbone cyclization of the recombinant cyclotide MCoTI-II, thereby allowing
the efﬁcient production of active homogenous species in high yields. Our results provide proof of
concept for using engineered Sortase A to produce cyclic MCoTI-II and should be generally applica-
ble to generating other cyclic cystine-knot peptides.
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Cyclotides are constrained cyclic peptides which contain a knot-
ted arrangement of three disulﬁde bonds. The presence of the
cyclized backbone and the cystine-knot framework in part make
cyclotides remarkably stable to chemical degradation and proteo-
lytic digestion [1–3], yet stability might be inﬂuenced by other fac-
tors such as shape and amino acid sequence. Initially discovered in
plants, cyclotides were shown to exhibit a wide range of biological
functions including oxytocic, insecticidal and antibacterial activi-
ties, to name a few [1,4]. Yet, how cyclotides are produced and cir-
cularized in nature has remained elusive. Recent data implicate
asparaginyl endopeptidase as a potential enzyme which mediates
transpeptidation between the N and C-termini of the cystine-knot
peptide during the circularization process in plants [5–7]. While
biochemical data using puriﬁed components to validate the pro-
posed role of asparaginyl endopeptidase are still lacking, experi-
ments in transgenic plants demonstrated that deletion of the
gene encoding asparaginyl endopeptidase abrogated production
of cyclotides [6,8], consistent with the notion that asparaginyl
endopeptidase might be involved in backbone cyclization.To date, there have been only a few reported methods for gen-
erating cyclic cystine-knot peptides in high yield and purity, with
the most common method for head-to-tail cyclization being native
chemical ligation [3,9,10]. More recent methods involve N? S acyl
transfer reactions on polypeptide backbones containing N-terminal
cysteine and a thiol-labile C-terminal Gly-Cys motif to generate
circular miniproteins [10]. However, enzyme-mediated cyclization
methods have started to garner attention due to their efﬁciency
and cost effectiveness compared to synthetic methods. In one pio-
neering example, the enzyme trypsin was used to mediate peptide
backbone cyclization of MCoTI [11], a cyclotide isolated from the
seeds of the fruit Momordica cochinchinensis and shown to exhibit
potent trypsin and matriptase inhibitory activity [2,12–16]. This
method takes advantage of the inherent trypsin binding property
of MCoTI-II to catalyze amide bond formation at a site that is rec-
ognized by trypsin and hence might not be suitable for generating
variants of cyclotides that do not bind to trypsin.
Other methods to generate recombinant cyclotides have been
described such as expressed protein ligation between a C-terminal
thioester and an N-terminal cysteine residue [17,18] as well as
intein-mediated protein trans-splicing in bacterial cells [19].
Despite these advances, there is still a need for versatile methods
that involve less puriﬁcation steps and enable efﬁcient cyclization
of cystine-knot peptides and their generation on a large scale in
good yields. Here we report a biomimetic approach for producing
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to catalyze amide backbone cyclization. The method described
herein utilizes an efﬁcient cyclization reaction, which allows the
production of active homogenous recombinant cyclotides in high
yields and is generally applicable to generating other cyclic cys-
tine-knot peptides.
2. Results and discussion
2.1. Biosynthesis of recombinant MCoTI-II
Our strategy for biosynthesis of cyclic MCoTI-II was to express a
folded version of MCoTI-II followed by an enzyme-mediated trans-
peptidation reaction to form an amide bond between the N- and C-
termini, thereby creating the cyclic peptide backbone. We selected
the enzyme Sortase A, a transpeptidase from Staphylococcus aureus,
which recognizes a consensus peptide sequence Leu-Pro-X-Thr-Gly
(X = any amino acid residue). This enzyme cleaves the amide bond
between Thr and Gly and catalyzes the ligation of the cleaved
sequence to a Gly-Gly-Gly motif, resulting in a contiguous Leu-
Pro-X-Thr-Gly-Gly-Gly polypeptide chain [20–22]. The Sortase A
reaction which occurs primarily as an intermolecular reaction in
S. aureus, has been recently exploited for generating circular pro-
teins or creating fusions of different proteins, as well as labeling
proteins at the N- or C-termini [23–25]. To generate cyclic MCoT-
I-II, we engineered a MCoTI-II construct (referred to as rMCoTI-II)
that comprises a Gly-Gly-Gly motif at the N-terminus and Leu-
Pro-Glu-Thr-Gly-Gly at the C-terminus (Fig. 1A). We also incorpo-
rated a 6Histidine (His) and glutathione S-transferase (GST) tag N
terminal to the Gly-Gly-Gly motif in order to utilize nickel nitrilo-
triacetic acid (Ni–NTA) afﬁnity chromatography for puriﬁcation
and take advantage of the solubility of GST as a carrier protein
(Fig. 1B). A Tobacco Etch Virus (TEV) cleavage site was also inserted
between GST tag and the Gly-Gly-Gly motif in order to remove the
His-GST tag after Ni–NTA puriﬁcation (Fig. 1B) and enable subse-
quent cyclization by Sortase A. Using this strategy, rMCoTI-II wasFig. 1. Strategy for biosynthesis of MCoTI-II. (A) Primary structures of native and engine
with disulﬁde bridges and the cyclic backbone (native) indicated. Cartoon was generated
loop 6 is colored in green while the engineered Sortase A recognition sequence is show
generating cyclic recombinant MCoTI-II (rMCoTI-II). (C) SDS–PAGE showing puriﬁcation
subjected to TEV protease in redox buffer at 4 C overnight. Sup, supernatant. FT, ﬂow texpressed in Escherichia coli and puriﬁed by Ni–NTA afﬁnity chro-
matography (Fig. 1C). The eluted fractions were pooled and incu-
bated overnight at 4 C with TEV protease under oxidative
conditions, which allowed folding of rMCoTI-II. A subsequent ﬁl-
tration step (MW cut-off 10 kDa) of the TEV reaction mixture
trapped the His-GST tag while allowing rMCoTI-II to pass through.
The ﬁltrate was then collected and further puriﬁed by reversed-
phase high performance liquid chromatography (RP-HPLC) to yield
oxidized rMCoTI-II which was later used for optimization of the
Sortase A-mediated cyclization reaction conditions (see below).
2.2. Sortase A-mediated cyclization of rMCoTI-II
While there could be great utility for the speciﬁc transpepti-
dase activity of Sortase A, the enzyme is signiﬁcantly limited by
poor reaction kinetics [26]. However, this limitation has recently
been addressed by using a directed evolution strategy to select
for Sortase A variants with improved catalytic activity [26]. This
strategy led to the identiﬁcation of four amino acid mutations
P94S/D160N/D165A/K196T within the catalytic domain of Sortase
A (Q60-K206) that, when combined, resulted in a 140-fold
increase in kcat/Km. We generated this mutant Sortase A (referred
to as m4SrtA) and conﬁrmed that the reaction kinetics were indeed
signiﬁcantly improved over the wild-type enzyme (Supp. Fig. 1).
Therefore, the use of m4SrtA would be advantageous for backbone
cyclization of cystine-knot peptides due to potentially higher reac-
tion yields compared to the wild-type enzyme. To our knowledge,
engineered Sortase A has not been used for backbone cyclization
of cyclotides.
We monitored the progress of the backbone cyclization reaction
mediated by m4SrtA by using liquid chromatography–mass spec-
trometry (LC–MS). Treatment of oxidized rMCoTI-II substrate (pre-
pared above) with m4SrtA under conditions which were optimized
as described in detail below led to a loss of 132 atomic mass units
as expected, owing to cleavage of two glycine residues on rMCoTI-
II and loss of a water molecule from amide bond formationered MCoTI-II. Loop regions and the Sortase A recognition sequence are highlighted
using MCoTI-II structure (PDB 1HA9) and the three disulﬁde bonds are highlighted;
n in salmon. (B) Schematic of the puriﬁcation and backbone cyclization method for
progress of rMCoTI-II. The elution fractions from Ni–NTA column were pooled and
hrough.
Fig. 2. Sortase A-mediated backbone cyclization of rMCoTI-II. (A) Reaction scheme of engineered Sortase A (m4SrtA) containing P94S/D160N/D165A/K196T mutations with
rMCoTI-II. (B) Representative LC trace showing oxidized rMCoTI-II (starting material, black) and cyclic rMCoTI-II (product, pink) obtained after treatment with m4SrtA. Peaks
1 and 2 correspond to isomers of oxidized rMCoTI-II (starting material). Reaction was carried out in 50 mM Tris pH 7.5, 100 mM NaCl, 10 mM for 72 h at 37 C. [m4SrtA],
50 lM; [rMCoTI-II], 100 lM. These conditions were selected based on reaction optimization described in Fig. 3 and Table 1. (C) Mass spectrometry analysis of oxidized
rMCoTI-II (peaks 1 & 2 of starting material). (D) Mass spectrometry analysis of oxidized cyclic rMCoTI-II product (peaks 1⁄ and 2⁄).
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two distinct peaks during the LC analysis, the two peaks have iden-
tical molecular weights (Fig. 2B and C, peaks 1 and 2). This is likely
due to the susceptibility of the amide bond between Asp4 and Gly5
residues within loop 6 (Fig. 1A) to isomerize, leading to the forma-
tion of succinimide and b-aspartyl isomers as observed in earlier
reports [12,13]. Regardless, both isomers undergo backbone cycli-
zation in the presence of m4SrtA, as observed by the shift in their
retention times and molecular weights (Fig. 2B and D, peaks 1⁄
and 2⁄).
Small scale optimization of the reaction conditions was per-
formed to favor intramolecular transpeptidation of the Gly-Gly-
Gly and Leu-Pro-Glu-Thr motifs engineered on the N- and C-termi-
nus of rMCoTI-II protein, respectively. By varying the enzyme (m4-
SrtA) and substrate (rMCoTI-II) concentrations, we found that
signiﬁcant improvements in reaction yield were observed as theenzyme concentration was increased to 50 lM (Fig. 3 and Table 1),
with no reaction observed at enzyme concentrations <10 lM. Also,
there was no additional beneﬁt to decreasing the substrate concen-
tration from 100 lM to 50 lM (Table 1). Therefore, we concluded
that the optimal concentrations of enzyme and substrate were
50 lM and 100 lM, respectively. In parallel, we looked at the effect
of time and temperature on the backbone cyclization yields. At
37 C and optimum enzyme and substrate concentrations, the
reaction proceeded slowly, with 75% of starting material becom-
ing cyclized in the ﬁrst 24 h, and the reaction continued to 90%
after 48 h and 95% after 72 h (Table 1 and Fig. 3). It is not clear
at this point why the reaction times are long, but we speculate that
the folded conformation of MCoTI-II precursor substrate might
contribute to this phenomenon. We also tested the above condi-
tions at 42 C, a temperature that has previously been reported
to be optimal for Sortase A enzymatic activity [21], and found that
Fig. 3. Optimization of backbone cyclization reaction conditions with varying Sortase A concentration and at different temperatures. Representative examples of LC traces
showing monitoring of backbone cyclization reaction with varying concentration of m4SrtA after 48 h at either 37 C (A) or 42 C (B). Integration of the peak area was
performed separately on the major early-eluting peak (peak 1) and its converted product (peak 1⁄), and the calculated % conversion for the major peak (peak 1 to peak 1⁄) was
reported in Table 1. Backbone cyclization reactions were set up in 50 mM Tris pH 7.5, 100 mM NaCl, 10 mM CaCl2 with varying molar concentration of m4SrtA enzyme as
indicated. Reactions were carried out in 320 ll volumes with rMCoTI-II concentration of 50 lM (0.21 mg/ml).
Table 1
Optimization of conditions for Sortase A-mediated backbone cyclization of rMCoTI-II.
% cyclization
rMCoTI-II (µM)
50 100 50 100 50 100
24 hours 48 hours 72 hours 
10 28 28 41 38 52 53
25 51 51 71 70 81 82
50 75 74 90 89 96 96
10 34 32 49 44 61 57
25 59 59 76 76 86 86
50 81 83 92 93 96 96
37
°C
42
°C
m
4 S
rtA
 (µ
M
) 
m
4 S
rtA
 (µ
M
) 
Backbone cyclization reactions were set up in 50 mM Tris pH 7.5, 100 mM NaCl, 10
mM CaCl2 with varying molar concentration of m4SrtA enzyme and linear rMCoTI-II at
the indicated temperature and time. Reactions were carried out in 170 – 320 µl volumes 
with MCoTI-II concentration of 0.21 – 0.42 mg/ml, respectively. Calculated %cyclization 
values are based on integration of the relative peak areas of the early-eluting peak and 
its cyclized product (peaks 1 and 1*, respectively, as shown in Figure 3). 
4490 K. Stanger et al. / FEBS Letters 588 (2014) 4487–4496there was a subtle improvement in reaction yields at the earlier
time points (i.e.75% at 37 C vs. 80% at 42 C, Table 1). However,
no differences in yields were observed at later time points between
37 C vs. 42 C (Fig. 3 and Table 1). We also found that engineeredm4SrtA enabled much more efﬁcient cyclization of rMCoTI-II com-
pared to wild-type Sortase A as determined by LC–MS analysis
(Fig. 4), a ﬁnding that is consistent with the notion of improved
catalytic activity for engineered Sortase A [26].
To investigate whether the m4SrtA-mediated cyclotide back-
bone cyclization is scalable, we utilized the optimal reaction condi-
tions from our small scale optimization to cyclize 70 mg of
oxidized rMCoTI-II, which was prepared as described above by
expression in E. coli as a His-GST-fusion protein (Fig. 1B). After
cleavage of the fusion tag and Ni–NTA puriﬁcation, rMCoTI-II was
resuspended in reaction buffer (0.4 mg/ml, 120 lM) and incubated
with m4SrtA enzyme (40 lM, 0.74 mg/ml) at 37 C. After an 88-h
reaction period, most of the starting material underwent backbone
cyclization (Supp. Fig. 2). The reaction was subsequently stopped
by adding Ni–NTA to the mixture to recover the His-tagged Sortase
A enzyme (which can be washed, eluted and re-used). The ﬂow
through (containing the cyclic rMCoTI-II) was collected and subse-
quently desalted on a C18 Sep-Pak column followed by lyophiliza-
tion of the eluate. Finally the cyclic rMcoTI-II was separated from
the minor unreacted acyclic species by preparative RP-HPLC and
puriﬁed to near homogeneity (Supp. Fig. 3). It is noteworthy that
the puriﬁed product elutes as a single sharp peak on a C18 column,
a column that is widely used to characterize cystine-knot peptides
routinely. The same material elutes as two peaks with different
retention times but identical molecular weights on a PLRP-S col-
umn (Supp. Fig. 3).
Fig. 4. Engineered Sortase A is more efﬁcient than the wild-type enzyme at
backbone cyclization of rMCoTI-II. Plot shows efﬁciency of backbone cyclization of
rMCoTI-II by wild-type (wtSrtA) and engineered Sortase A (m4SrtA) at different
time points. Fraction of cyclized rMCoTI-II was determined from LC–MS analysis
based on quantiﬁcation of the relative peak areas of peaks 1 and 1⁄. Reactions were
run for the indicated times at 37 C in 50 mM Tris pH 7.5, 100 mM NaCl, 10 mM
CaCl2 with an enzyme concentration (m4SrtA or wtSrtA) of 50 lM and [rMCoTI-II] of
150 lM. N-terminal His-tagged wild-type and engineered Sortase A enzymes were
used. The values represent the average from triplicate independent experiments
and the error bars are standard error of the mean (S.E.M.).
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NMR was used to qualitatively evaluate the integrity of the
solution structure of puriﬁed cyclic rMCoTI-II by comparing its
measured NOESY spectra to spectra that were back-calculated
based on the published coordinates and assignments of MCoTI-II
(PDB 1HA9) [14] (Fig. 5). Only the structure of the region spanning
residues Gly5-Gly34 was evaluated; this region covers the three
disulﬁde bonds and loops 1–5, but excludes most of loop 6, which
contains the additional Sortase A recognition sequence. We specu-
lated that the change in amino acid composition of loop 6 would
have little to no effect on the structure of the rest of the molecule
relative to the wild-type molecule. Indeed, there was an excellent
overlay of the region containing the NH-aH NOESY cross peaks in
the cyclic rMCoTI-II spectra and the back-calculated spectra of
MCoTI-II derived from the published assignments (Fig. 5). These
data are consistent with the notion that cyclic rMCoTI-II adopts a
fold that is similar to native MCoTI-II [14]. The residual visible
peaks in the measured data likely correspond to extra residues in
loop 6 and can also be in part explained by local structural dynam-
ics and peaks from exchange with solvent protons. It is also note-
worthy that the back-calculation method does not take into
account solvent exchange and was based on the lowest energy
structure of the NMR ensemble deposited in the protein data bank
(PDB entry 1HA9 consisting of thirty conformers), which might
also explain the appearance of some of the extra peaks in the mea-
sured spectra.
Biochemical characterization of cyclic rMCoTI-II was carried out
to assess the chemical and proteolytic stability of the puriﬁed
recombinant peptide. Recombinant MCoTI-II variants exhibited
notable stability in a variety of harsh conditions including PBS at
37 C and 65 C and in simulated gastric ﬂuid (SGF) for several days
(Fig. 6), as expected for a cystine-knot peptide. To further validate
the correct fold of the recombinant MCoTI-II variants, bioactivity ofrMCoTI-II was assed via trypsin enzymatic assays. Cyclic rMCoTI-II
inhibited trypsin activity with a Ki of 1.5 ± 0.2 nM, a potency simi-
lar to what has been previously observed for native cyclic MCoTI-II
[27], whereas the acylic rMCoTI-II variant exhibited a 2-fold lower
inhibitory effect with a Ki of 3.0 ± 0.5 nM (Table 2 and Fig. 6D).
Overall, these data support the notion that cyclic rMcoTI-II,
obtained by Sortase A cyclization, behaves in a similar fashion to
the native molecule [28], and also indicate that cyclization does
not seem to contribute strongly to the biological activity of MCoT-
I-II. Moreover, we generated a synthetic linear version of MCoTI-II
(non-folded, referred to as acyclic Acm-sMCoTI-II), with all cys-
teine residues protected with S-acetamidomethyl (Acm) groups
to prevent spontaneous disulﬁde formation and subsequent fold-
ing (Supp. Fig. 4). This linear peptide does not inhibit trypsin activ-
ity (Table 2 and Fig. 6D) and is less stable than the folded
counterpart under harsh conditions such a PBS at 65 C or simu-
lated gastric ﬂuid (Fig. 6A–C). These observations validate that
folding of the cystine-knot peptide is required for stability and
trypsin-inhibitory function.
3. Conclusion
In summary, we developed a strategy for generating cyclotides
via recombinant expression coupled with Sortase A-mediated
backbone cyclization. Several conditions were tested to obtain
the highest cyclization efﬁciency as measured by LC–MS which
included varying substrate and enzyme concentrations, reaction
time and temperature. Optimized conditions for cyclization were
determined to be 100 lM rMcoTI-II substrate and 40 lM m4SrtA
enzyme incubated for 96 h at 37 C with gentle stirring. Optimiza-
tion of the Sortase A reaction conditions combined with the use of
engineered Sortase A [26], which has signiﬁcantly improved activ-
ity over wild-type, led to almost quantitative cyclization yields.
The cyclic rMCoTI-II generated through this methodology displays
remarkable chemical and protease stability and is a potent trypsin
inhibitor, supporting the notion that recombinant expression gen-
erates correctly folded MCoTI-II species as indicated by our NMR
studies. Moreover, our data indicate that backbone cyclization post
folding is a good approach for generating cyclic MCoTI-II. Interest-
ingly, backbone cyclization of MCoTI-II does not seem to be
required for its trypsin inhibition or stability, at least at high tem-
perature or low pH.
The Sortase A-mediated backbone cyclization process requires
the introduction of new amino acid residues into the cystine-knot
peptide to enable their cyclization. The addition of an LPETGGG
amino acid sequence into loop 6 seemed to have minimal effects
on folding of MCoTI-II. This observation is consistent with recent
studies which demonstrated that grafting sequences as long as six-
teen amino acid residues into loop 6 does not alter the disulﬁde
bond connectivity within MCoTI [29]. Moreover, the MCoTI-ll scaf-
fold has been engineered to bind to a range of protein targets
including HMD2 [29], beta-tryptase, human leukocyte elastase
and matriptase [16,27,30,31], suggesting that the framework itself
has plasticity to accommodate different sequences. However,
introducing the Sortase A recognition sequence into other loop
regions within the framework might pose a problem and hence
would need to be carefully assessed on a case-by-case basis. Not-
withstanding these limitations, the method described here pro-
vides a robust and efﬁcient approach for in vitro production of
cyclic cystine-knot peptides and can potentially be extended to
produce backbone-cyclized cystine-knot peptides in vivo by co-
expression with Sortase A. Finally, while this manuscript was in
preparation, a study demonstrated the use of wild-type Sortase A
to cyclize another cystine-knot peptide, the cyclotide kalata B1
[32], which was obtained via chemical synthesis and oxidative
Fig. 5. NMR characterization of cyclic rMCoTI-II. (A) The ﬁngerprint region of the 300 ms mixing time 2D 1H-1H NOESY spectrum of cyclic rMCoTI-II (black) overlaid with the
back-calculated data (red). The back-calculation of the 300 ms NOESY using a distance cut-off of 0.5 nm was done in Auremol (Bruker Reports 2004, 154/155, 11–14) utilizing
the complete relaxation matrix approach. The input used in the calculation was based on the assignments and the Protein Data Bank (www.pdb.org) entry 1HA9 both
published earlier [14]. The 300 ms mixing time NOESY spectrum was measured using freeze dried peptide dissolved at a concentration of 3 mM in 180 ll 5%D2O/95%H2O. The
pH was measured to be 2.2. Spectra were recorded at 600 MHz proton frequency and 298 K using a TXI cryo-probe. Residual peaks correspond to either additional amino acid
residues present in loop 6, solvent exchange or conformational dynamics within cyclic rMCoTI-II. (B) The same 2D 1H-1H NOESY spectrum of cyclic rMCoTI-II showing a
sequential walk through the amide to a-proton correlations for selected parts of the sequence.
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Fig. 6. Stability and biological activity of rMCoTI-II variants. (A–C) Chemical and proteolytic stability of peptide variants in PBS at 37 C (A), PBS at 65 C (B) and simulated
gastric ﬂuid (C) for one week. Peptides include cyclic (squares) and acyclic (solid circles) recombinant MCoTI-II, and acyclic (open circles) synthetic MCoTI-II with all cysteine
residues protected with S-acetamidomethyl (Acm) groups to prevent spontaneous disulﬁde formation and subsequent folding. (D) Inhibition of trypsin by MCoTI-II variants.
Competition experiments for peptides were carried out in the presence of trypsin (0.44 nM) and L-Arg-AMC (75 lM) as substrate. The error bars represent the standard error
of the mean of three independent experiments.
Table 2
Inhibition constant (Ki) for acyclic and cyclic versions of folded and non-folded
MCoTI-II measured at two different concentrations of trypsin.
Peptide Ki [Trypsin], 440 pM
Ki 
[Trypsin], 5.3 pM
Cyclic rMCoTI-II 1.5 ± 0.2 nM 2.1 ± 0.3 nM 
rMCoTI-II (acyclic) 3.0 ± 0.5 nM 4.1 ± 0.5 nM 
Acyclic Acm-sMCoTI-II n.i. n.i. 
rMCoTI-II, recombinant 
sMCoTI-II, synthetic  
n.i., no inhibition 
Acm, acetamidomethyl (protecting group on cysteine residues) 
     , cartoon depicting cysteine residues 
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thetic peptides, our study here reports a novel method for generat-
ing recombinant MCoTI-II in E. coli as a GST-fusion protein,
allowing the production of multi gram quantities. Furthermore,we utilize an engineered version of Sortase A which is substantially
more efﬁcient than the wild-type enzyme at cyclizing a cystine-
knot peptide, and describe in detail optimal conditions for the
cyclization reaction. Our data demonstrate the potential utility of
engineered Sortase A in backbone cyclization of cystine-knot
peptides.
4. Methods
4.1. Expression and puriﬁcation of Sortase A
The Sortase A gene (encoding amino acids Q60-K206) was sub-
cloned into a pET expression vector (Novagen, EMD Millipore) con-
taining either an N- or C-terminal 6Histidine tag. Four mutations
P94S, D160N, D165A, and K196T, were introduced by site-directed
mutagenesis (Quikchange, Agilent Technology). Wild type and
mutant Sortase A were expressed and puriﬁed producing both N-
and C-terminally tagged proteins. Expression in E. coli was carried
out according to standard protocols in BL21-Rosetta™ 2 DE3 cells,
LB (Luria–Bertani) medium and induction at 16 C for 20 h with
0.5 mM IPTG (isopropyl b-D-thiogalactoside). The cells were har-
vested by centrifugation and resuspended in lysis buffer (50 mM
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pyranoside, 5 U/ml Benzonase, Roche protease inhibitor tablet).
Cells were passed through a microﬂuidizer three times and clari-
ﬁed by centrifugation at 30000 g for 30 min at 4 C. Sortase A
was puriﬁed from the supernatant on Ni–NTA agarose using stan-
dard protocols [33]. Constructs with a N-terminal 6xHis tag
expressed at levels approximately 3-fold higher than those with
a C-terminal His tag (yields 50 mg/l vs. 15 mg/l, respectively).
Each construct (wild type enzyme with N- and C-terminal His
tag, and mutant enzyme with N- and C-terminal His tag) were
puriﬁed to high purity from the Ni–NTA alone, with no additional
puriﬁcation steps required. Eluate from the Ni–NTA was pooled,
dialyzed into 50 mM Tris pH 7.5, 300 mM NaCl, concentrated to
5–10 mg/ml, and frozen at 80 C for storage.
4.2. Sortase A activity assays
The activities of recombinant Sortase A and Sortase A mutants
were tested using a FRET peptide substrate Dabcyl-LPETG-Edans
(AnaSpec #62231). Each enzyme (1 lM) was incubated in reaction
buffer (50 mM Tris pH 7.5, 150 mM NaCl) with 50 lM FRET sub-
strate at room temperature. Fluorescence was measured every
15 min for 18 h in a kinetic microplate reader (Spectramax-M5,
Molecular Devices, Sunnyvale, CA) with an excitation wavelength
of 350 nm and an emission wavelength of 495 nm.
4.3. Optimization of backbone cyclization conditions
Cyclization reactions (170–320 ll) were set up in 50 mM Tris
pH 7.5, 100 mM NaCl, 10 mM CaCl2 at the indicated temperature
with varying molar concentrations of m4SrtA enzyme and pure oxi-
dized rMCoTI-II (67–71 lg). Samples (20 lg) were collected at dif-
ferent time points and injected into an analytical LC/MS (Agilent
1260 Inﬁnity), and the area under the A214 nm peak was quanti-
ﬁed. Samples were analyzed on a PLRP-S reversed phase column
(Agilent, PL1912-1802) with a ﬂow rate of 0.05 ml/min and a linear
gradient of 5–60% acetonitrile with 0.05% triﬂuoroacetic acid over
6 min.
4.4. Biosynthesis, backbone cyclization and puriﬁcation of rMCoTI-II
variants
MCoTI-II was fused to an N-terminal His-GST-TEV tag and
expressed as soluble protein in E. coli using standard protocols.
Proteins were expressed in 44H9 cells and grown in Complete
C.R.A.P. media in a 10 L fermenter at 37 C. The cells were subse-
quently harvested by centrifugation and frozen at 80 C. After
thawing, the cells were resuspended in Lysis Buffer (50 mM Tris
pH 8.0, 300 mM NaCl, 10 mM Imidazole, 2 mM b-Mercaptoethanol,
0.4% n-Dodecyl-b-D-Maltopyranoside, 5 U/ml Benzonase (Sigma
#E1014), Roche Protease inhibitor tablets (#11 873 580 001))
and passed through a microﬂuidizer three times to ensure lysis.
Insoluble debris was removed by centrifugation at 30000g for
30 min at 4 C.
rMCoTI-II was captured from the lysate by Ni–NTA agarose
(Qiagen). The resin was washed with 5 column volumes (CV) of
Wash Buffer (50 mM Tris–HCl pH 8.0, 300 mM NaCl, 20 mM imid-
azole, 2 mM BME) and the fusion protein eluted with 3–4 CV of
Wash Buffer including 400 mM imidazole. The elution fractions
were pooled and TEV protease (250 lg) was added per 20 mg of
rMCoTI-II fusion protein to cleave its N terminal TEV sequence
(ENLYFQG.). The TEV cleavage reaction was supplemented with
3 mM reduced glutathione and 0.3 mM oxidized glutathione and
incubated overnight at 4 C with gentle shaking. The rMCoTI-II
was isolated by ﬁltration (10 kDa cutoff ﬁlter, Amicon Stirred Cell
Device, Millipore) which trapped the glutathione S-transferase(GST) and TEV proteins while allowing rMCoTI-II to pass through,
followed by de-salting on a C18 Sep-Pak column (Waters
#WAT043345).
The backbone cyclization reaction of oxidized rMCoTI-II to pro-
duce cyclic MCoTI-II was carried out in the presence of mutant Sor-
tase A (N-term His-Q60-K206. P94S/D160N/D165A/K196T).
rMCoTI-II (70 mg) was resuspended to 0.4 mg/ml (0.12 mM) in
cyclization buffer (50 mM Tris pH 7.5, 100 mM NaCl, 10 mM CaCl2)
and incubated with m4SrtA (0.74 mg/ml, 40 lM) at 37 C. The reac-
tion progress was monitored by LCMS. After 88 h, 95% conver-
sion was observed, and the reaction was stopped by removal of
His-tagged m4SrtA with washed Ni–NTA agarose in the presence
of 5 mM imidazole (which is required to reduce non-speciﬁc bind-
ing to the resin). Both the ﬂow-through containing cyclic rMCoTI-II
and 3 CV of wash buffer used to wash the column were collected
and pooled (Wash buffer: 50 mM Tris pH 8.0, 300 mMNaCl, 20 mM
imidazole). The obtained fraction was desalted on a C18 Sep-Pak
column and lyophilized to yield 83 mg of crude product. Half of
the crude (36 mg) was resuspended in water and further puriﬁed
by RP-HPLC (Varian) on a C18 column (Higgins Analytical # RS-
2520-W181) using a gradient of 2–50% acetonitrile with 0.05% tri-
ﬂuoroacetic acid over 40 min at a ﬂow rate of 20 ml/min. The cyclic
rMCoTI-II material eluted as a sharp peak at 18.5 min and fractions
were analyzed by analytical LC/MS (Agilent 1200 series) to conﬁrm
folding and purity before pooling. The ﬁnal yield of pure cyclic
rMCoTI-II was 15 mg. Cyclized peptide was analyzed on a XDB-
C18 reversed phase column (Agilent, 927975-902) using a ﬂow rate
of 0.05 ml/min and a linear gradient of 2–60% acetonitrile with
0.05% formic acid over 6 min. The acyclic rMCoTI-II was prepared
in an identical fashion with the exception of the Sortase A-medi-
ated cyclization step.4.5. Synthesis of linear MCoTI-II variant
Linear MCoTI-II corresponding to the amino acid sequence of
the recombinantly prepared MCoTI-II was assembled with a CEM
Liberty Blue microwave peptide synthesizer and manual synthesis
using standard Fmoc chemistry procedures [34] and puriﬁed by
RP-HPLC. All cysteine residues were capped with S-acetamidom-
ethyl (Acm) protecting groups to prevent folding. The ﬁrst 34 res-
idues were assembled on the microwave synthesizer, the last 8
residues were added manually and the last 14 residues were dou-
ble-coupled due to a difﬁcult synthetic sequence region. The resi-
dues Asp7-Gly8 were introduced as a dipeptide building block
incorporating a 2-hydroxy-4-methoxybenzyl (Hmb) protecting
group on the glycine backbone nitrogen to suppress aspartimide
formation [35]. The peptide purity and identity were conﬁrmed
by analytical LC–MS on an Agilent 1260 Inﬁnity system equipped
with a PLRP-S reversed phase column.4.6. Stability assays
Cystine-knot peptides were incubated at a concentration of
0.3 mg/ml in PBS at 37 C or PBS at 65 C. At the indicated times,
10 ll (3 lg) aliquots were removed from the reaction and mixed
with 2.6 lg of internal standard peptide. Samples were immedi-
ately analyzed by analytical LC/MS (Agilent 1200 series) and the
area under the A214 nm peak was quantiﬁed. Stability of the pep-
tides in simulated gastric ﬂuid were carried out at 37 C in a similar
fashion except, the aliquots were ﬁrst quenched with 40 lL of
0.25 M NaOH prior to addition of the internal standard. To prepare
simulated gastric ﬂuid, 2 g of sodium chloride, 43 mg of sodium
taurocholate, 16 mg of lecithin and 100 mg of pepsin were dis-
solved in Milli-Q water (18.2 MX cm1) and adjusted to a pH of
1.2 with 37% hydrochloric acid. EETI-II wild-type sequence with
K. Stanger et al. / FEBS Letters 588 (2014) 4487–4496 4495Cys residues protected with S-acetamidomethyl (Acm) group was
used as the internal standard peptide.
4.7. Trypsin inhibition assays
Trypsin inhibition assays, which resulted in substrate-indepen-
dent inhibition constants were performed as previously described
[27,36]. Brieﬂy, TPCK treated trypsin from bovine pancreas (sigma)
was ﬁrst standardized by active site titration with p-nitrophenyl-
p0-guanidinobenzoate (NPGB, sigma) according to the method
described by Chase et al. [37]. All kinetic measurements were per-
formed in 50 mM Tris pH 7.6, 150 mM NaCl, 0.01% TritonX-100,
0.01 sodium azide buffer in triplicate and ﬂorescence measure-
ments (Ex. 360 nm, Em. 465 nm) were done in 96-well NUNC
F96 plates using a SpectraMax M5e (Molecular Devices) multi-
mode plate reader. KaleidaGraph 3.6 was used for data analysis.
To determine the Michaelis–Menten constants (KM) for the sub-
strates used for the inhibition assays, the initial reaction rate (vi) of
the degradation of carbobenzoxy-L-arginine-7-amino-methyl-
coumarin (L-Arg-AMC, sigma) by trypsin (45 nM) was determined
for a series of concentrations ([Si]) of the ﬂuorogenic substrate
(750–5 lM). KM was calculated by non-linear regression to yield
a KM of 61.7 ± 8.4 lM. The KM for N-p-tosyl-glycine-proline-argi-
nine-7-amido-4-methylcoumarin (tosyl-GPR-AMC, Sigma) was
determined in a similar fashion, except 1 nM trypsin was incu-
bated with 150–0.05 lM substrate to yield a KM of 7.0 ± 0.6 lM.
The KM is the mean of triplicate measurements with standard devi-
ation reported as the error.
The normalized residual proteolytic activity (vi/vo) of trypsin
toward the 75 lM L-Arg-AMC or 5 lM tosyl-GPR-AMC at different
concentrations of MCoTI-II variants (Io) was determined for 0.4 nM
and 0.005 nM trypsin (Eo), respectively. Product formation was
monitored after pre-incubation of protease with peptides for
90 min at room temperature. Apparent inhibition constants ðKappi Þ
were calculated by ﬁtting the Morrison Eq. (1) for tight-binding
inhibitors using non-linear regression. Substrate-independent
inhibition constants Ki were calculated from K
app
i and the measured
KM values according to Eq. (2). The inhibition constants measured
at two different trypsin concentrations are in good agreement as
shown in Table 2.
v
vo
¼ 1 ðEo þ Io þ K
app
i Þ 
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
ðEo þ Io þ Kappi Þ
2  4EoIo
q
2Eo
ð1Þ
K i ¼ K
app
i
1þ ½SKM
ð2Þ4.8. NMR
1H spectra were recorded on Bruker Avance 600 and 800 NMR
spectrometers equipped with cryogenically cooled probes (Bruker,
Karlsruhe, Germany) and operating at proton resonance frequen-
cies of 500 MHz and 800 MHz, respectively. Water suppression in
1 and 2D spectra was achieved by using the excitation sculpting
pulse sequence [38]. All two-dimensional spectra were collected
in the phase sensitive mode using time proportional phase incre-
mentation [39]. Spectra were recorded at 298 K and calibrated to
the chemical shift of DSS at 0 ppm. NOESY [40] and TOCSY [41]
two-dimensional data sets were recorded with 4 k data points in
the acquisition dimension and 512 data points in the indirect
dimension. NOESY spectra were recorded with a mixing time of
200 ms and TOCSY spectra were recorded with spin-lock times of
60 ms using the DIPSI-2 [42] sequence for isotropic mixing. The
time-domain data were processed using the software TopSpin(Bruker, Karlsruhe); evaluation and visualization was performed
using the program AURELIA [43]. X-ray and NMR structures of
MCoTI-II were obtained from the Brookhaven Protein Database.
4.9. Back-calculation of NOESY spectra to evaluate structural integrity
Using the relaxation-matrix approach [44] as implemented in
the program RELAX [45], the published structure of MCoTI-II
(PDB entry 1HA9) was used to back-calculate NOESY spectra based
on the published assignments [14]. These spectra were aligned to
the experimental spectra of rMCoTI-II and analyzed by optical
comparison of peak position and peak intensity. The only changes
made to align the spectra better were small corrections to the
chemical shift, likely due to the slightly different conditions of
the TOCSY used for assignment. Exchange with solvent was not
considered in the back calculation leading to several peaks in the
measured spectrum not appearing in the back calculation.
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